COMPANY

Okogen

Keywords: infectious disease conjunctivitis Adenoviral Conjunctivitis OKG-0301

Location: Plano, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $3.3M · announced Dec 11, 2024 Company release ↗
Source quote
- Dec 11, 2024 · Company release ↗
  “Plano, TX – December 11, 2024 – Okogen Inc. , a company specializing in innovative eyecare solutions, today announced the successful completion of $3.3 million in financing”

Raises announced in these releases: $3.3M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Dec 11, 2024 Raise Undisclosed round · $3.3M source ↗
Feb 11, 2019 Trial start Phase 2: OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03856645	OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis	Phase 2	Unknown status (ClinicalTrials.gov)	Feb 11, 2019	Jun 30, 2022 (estimated)